Brief: Equillium Announces Initiation Of Phase 1 Study Of Eq102, A First-In-Class Multi-Cytokine Inhibitor Of Il-15 And Il-21 Targeting Celiac Disease
02/11/2022 12:29
Nov 2 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM ANNOUNCES INITIATION OF PHASE 1 STUDY OF EQ102,
A
FIRST-IN-CLASS MULTI-CYTOKINE INHIBITOR OF IL-15 AND IL-21
TARGETING CELIAC DISEASE
Source text for Eikon: ID:nBw8jYsZma
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations